Comparative Pharmacology
Head-to-head clinical analysis: PRISCOLINE versus SODIUM NITROPRUSSIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRISCOLINE versus SODIUM NITROPRUSSIDE.
PRISCOLINE vs SODIUM NITROPRUSSIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Priscoline (tolazoline) is a competitive alpha-adrenergic receptor antagonist; also has direct vasodilatory and histamine-like effects, leading to peripheral vasodilation and decreased peripheral vascular resistance.
Sodium nitroprusside is a prodrug that releases nitric oxide (NO) in vascular smooth muscle cells, activating guanylate cyclase and increasing cGMP, leading to vasodilation of both arterial and venous vessels.
10-50 mg subcutaneously or intramuscularly every 4-6 hours; intravenous administration (10 mg slow IV push) reserved for acute vasospastic episodes.
Intravenous infusion: Initial 0.3-0.5 mcg/kg/min; titrate up to 10 mcg/kg/min, maximum 10 mcg/kg/min for up to 10 minutes. Usual therapeutic dose: 3 mcg/kg/min. Max cumulative dose: 3.5 mg/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults; prolonged in renal impairment.
Sodium nitroprusside itself has a half-life of approximately 2 minutes (converted to cyanide in erythrocytes); the metabolite thiocyanate has a terminal half-life of 2.7-7 days (prolonged in renal impairment, requiring monitoring)
Primarily renal excretion of unchanged drug (approximately 90%); minor fecal excretion (<10%).
Renal: approximately 75% as thiocyanate (metabolite) with 25% unchanged; biliary/fecal: minimal (<5%)
Category C
Category C
Vasodilator
Vasodilator